Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
about
New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisonsDabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of SubgroupsNew oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney diseaseDirect thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationFactor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillationRisk impact of edoxaban in the management of stroke and venous thromboembolismHow we treat bleeding associated with direct oral anticoagulantsChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewNovel oral anticoagulants and the 73rd anniversary of historical warfarinHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationApixaban and oral implicationsSecondary stroke prevention: challenges and solutionsAntithrombotic management of atrial fibrillation in the elderlySafety of new oral anticoagulant drugs: a perspectiveThe critical care management of spontaneous intracranial hemorrhage: a contemporary reviewNet clinical benefit of oral anticoagulants: a multiple criteria decision analysisDetecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke.Management of ischaemic stroke in the acute setting: review of the current status.The Reversal of Direct Oral Anticoagulants in Animal Models.A generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trialsDirect anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial.Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures.Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillationPredicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trialsCost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settingsNovel oral anticoagulants in non-valvular atrial fibrillation.Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for StrokeNon-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.Truly low and high thromboembolic risk - impact of risk scores in real life.Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60.Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary reportComparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials.Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis.Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis.
P2860
Q21132464-204F2A08-D121-4659-8DE5-9A1FEECF8415Q21284803-82AC2E59-77F3-44A0-9654-74D0D83DBE3CQ24192938-315E154F-89D5-46D4-8899-2B7EE2FC6196Q24197843-A9A75CFD-F855-40EF-9D50-118507B1DB18Q24200497-B8E54C05-B64D-4C4F-A478-F36F70A1AC1FQ26738846-3D7EB8FF-6D6C-4827-92D9-34EE4ED4CAD1Q26748343-A7B328C8-BB18-4599-963D-99807AB7E3BCQ26765949-C0E83184-270F-4CD4-AC19-52B6BCFED3A1Q26771544-5F00E99F-CF5D-45EC-9E3D-02D4F208F6EFQ26776413-A106F3DF-EC69-4B50-8651-D6958C690EB2Q26780328-E3C89D99-3411-4932-8A03-6921AD5B8545Q26795568-E9B15D6A-133D-4A58-90ED-EFD765A3BC0EQ26827113-D6E2DBCF-59D1-4964-9385-D71B371651B3Q27016072-949AD9C1-5A55-4DAA-B873-69CDB8E9E6F4Q28067962-9A0D175E-D113-4FFC-B9E1-E5B7513A9FEBQ28546594-AF0682B0-7D8A-4A3C-A9D0-2A9991A2D862Q30249817-DEF28DDB-AFB8-49A0-B43E-6C6A588E7951Q30431467-2A6619F7-3677-4FDA-B565-B07D17A9DE58Q30491580-A13BD4C7-9F94-482B-982E-396259C40520Q30543580-0968A141-62F8-4D4A-9145-795A421CDAD3Q30595943-49F16562-FB55-481A-BD28-68F06F333B5DQ30830699-4F2FA28C-484F-4EDD-B474-A8D0D32EAEFFQ31131437-5B4ADF8A-93A1-4226-B7D0-207B540D971FQ33656869-DCF653EF-705C-4582-8735-38A5C7A3C28AQ33714864-6959522E-34DF-4CB1-A9D4-741B159C4CB9Q33960850-0F6F6AEC-CBEE-4902-9489-525906BE13C6Q34099930-74843AC0-C848-4ED5-9E0A-578EA1078303Q34311567-A14DD34A-89C1-44BA-BDAF-49BDE7AA1844Q34604533-E5306F50-2208-4A9A-8D2A-ED45C4A40D56Q34666804-570EA337-88E3-40CB-B248-54F72776E88CQ34670524-6ADD261B-1932-49BE-A3EA-6B1B1FB77FDFQ34672746-DA87DE84-E2D5-45BC-965A-C442F6389109Q34821791-4D382F0D-375A-480A-8C40-ED38B2D271C5Q35044615-E1511BA5-1D2C-4C2D-AE1B-374153F6AD26Q35065354-D3199695-1045-4C24-B35A-5EC9664045A6Q35079761-5E2CA1B7-29DB-4F0E-A7ED-17F979B1B871Q35149499-71A12736-35E5-4E91-90B2-A8E60993E6F5Q35205072-417820EB-DDE2-4D51-8FEC-00F30EFC5A87Q35550883-2DE1CB6A-42C9-4E94-81F4-5A0B54B277C2Q35681742-E10C56FB-23A7-480C-802B-1EBB7BD6ADBE
P2860
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Meta-analysis of efficacy and ...... ents with atrial fibrillation.
@en
type
label
Meta-analysis of efficacy and ...... ents with atrial fibrillation.
@en
prefLabel
Meta-analysis of efficacy and ...... ents with atrial fibrillation.
@en
P2093
P921
P1476
Meta-analysis of efficacy and ...... ients with atrial fibrillation
@en
P2093
Avi Shimony
Corey S Miller
Mark J Eisenberg
P304
P356
10.1016/J.AMJCARD.2012.03.049
P407
P577
2012-04-24T00:00:00Z